Overview
CRDF market data
Price History
CRDF price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.69 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.42 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -8,526.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.76 – $3.31 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $79.3M · P/B 4.17 · P/S 151.00.
Company News
William Blair Downgrades Cardiff Oncology to Market PerformBenzinga · Aug 12, 2026, 7:03 PM
12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga · Aug 11, 2026, 9:06 PM
Cardiff Oncology Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $104.000K Beat $70.714K EstimateBenzinga · Aug 11, 2026, 8:40 PM
8-K filing — Cardiff Oncology, Inc. (CRDF)SEC EDGAR · Jul 16, 2026, 12:38 PM
Crude Oil Moves Lower; US Producer Prices Fall 0.3% In JuneBenzinga · Jul 15, 2026, 4:03 PM
Dow Gains Over 150 Points; Morgan Stanley Profit Tops ViewsBenzinga · Jul 15, 2026, 1:43 PM
Cardiff Oncology shares are trading lower after the company announced a $10 million offering of 8,571,429 shares of its common stock and accompanying warrants at $1.05 per share and accompanying warrant.Benzinga · Jul 15, 2026, 12:04 PM
Cardiff Oncology Announces $10M Registered Direct Offering Of 8,571,429 Shares An Accompanying Warrants At $1.05 Per Share And Accompanying WarrantBenzinga · Jul 15, 2026, 12:03 PM
Craig-Hallum Downgrades Cardiff Oncology to Hold, Lowers Price Target to $2Benzinga · Jun 3, 2026, 5:45 PM
Cardiff Oncology Announces Presentation Of Phase 2 Trial Data For RAS-Mutated mCRC Treatment Onvansertib At ASCO Annual Meeting On June 2Benzinga · Jun 2, 2026, 1:14 PM